A preliminary evaluate of negative effects from common medication used to deal with diabetes and weight problems exhibits no hyperlink with suicidal ideas or actions, the U.S. Meals and Drug Administration stated Thursday.
However the company additionally stated officers can’t definitively rule out that “a small threat might exist” and that they will proceed to look into stories concerning greater than a dozen medication, together with Ozempic, Wegovy, and Mounjaro. Sufferers taking the medication ought to report any considerations to well being care suppliers, the FDA stated.
The evaluate follows a latest federally funded examine that confirmed that individuals taking semaglutide, the medicine in Ozempic and Wegovy, had a decrease threat of suicidal ideas than these taking different medication to deal with weight problems and diabetes. The evaluate got here after European regulators stated they have been investigating anecdotal stories that individuals taking semaglutide had ideas of self-harm.
“Our preliminary analysis has not discovered proof that use of those medicines causes suicidal ideas or actions,” the FDA report stated.
The company is analyzing stories associated to greater than a dozen medication accredited since 2005 which can be generally known as GLP-1 receptor agonists. The medicines assist management blood sugar ranges and scale back the chance of coronary heart illness in individuals with sort 2 diabetes. A few of the medication are additionally used to assist individuals with weight problems or who’re chubby shed kilos.
